More than half of today’s unicorn health startups haven’t published any influential research — and some experts say that raises the risk of another Theranos

In a new study, an early Theranos whistle-blower and Stanford professor of medicine analyzes a cluster of $1 billion healthcare startups and finds very few are publishing high-impact papers.